Pharmaceutical cannabinoid companies in Canada, US release positive results

Avicanna, a Toronto-based biopharmaceutical company focused on the development, manufacturing and sales of plant-derived cannabinoid-based products, said that in 2022 it had secured its first pharmaceutical partnership, made several drug submissions, and reached its 19th international market, and looks to build on that this year.

Meanwhile, Pennsylvania-based Zynerba Pharmaceuticals, which describes itself as “an orphan-focused, neuropsychiatric, biopharmaceutical company taking a different and exciting transdermal approach to cannabinoids”, reduced its net loss last year, while continuing with a clinical trial of a medication for patients suffering from a genetic mutation that causes intellectual disabilities and cognitive impairment.